艾博兹医药
Location: China
Employees: 1-10
Total raised: $75M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.11.2021 | Series A | $75M | - |
Mentions in press and media 11
| Date | Title | Description |
| 31.03.2023 | Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China | SHANGHAI, March 31, 2023 /PRNewswire/ -- Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients in China, today announced the development plans of a first-in-class nove... |
| 27.12.2022 | Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies | SHANGHAI, Dec. 27, 2022 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze") announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. ("Yonghe") to devel... |
| 26.12.2022 | Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies | SHANGHAI, Dec. 26, 2022 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze") announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. ("Yonghe") to devel... |
| 03.08.2022 | Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies | SHANGHAI, Aug. 3, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government of Chengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investmen... |
| 02.08.2022 | Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies | SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government of Chengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investmen... |
| 30.11.2021 | Vivo Capital, Co-Leads a $75m Series A Round of Financing in Ablaze Pharmaceuticals | - |
| 30.11.2021 | Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market | - |
| 29.11.2021 | Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market | SHANGHAI and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze"), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies... |
| 29.11.2021 | Ablaze Pharmaceuticals Raises $75M in Series A Financing | Ablaze Pharmaceuticals, a Shangai, China and San Diego, CA-based clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, raised... |
| 29.11.2021 | Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market | SHANGHAI and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze"), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies... |
Show more